- All
- Product Management
- News
- Introduction
- Enterprise outlets
- FAQ
- Enterprise Video
- Enterprise Atlas
Chuangyuan Biotechnology's proprietary strains have been granted a national invention patent for research related to alcoholic liver injury.
Recently, the invention patent certificate for "An Application of Weizmannia coagulans IOB502 Segmented Fermentation Agent in Alcoholic Liver Injury" (Patent No.: ZL 202311841530.4) independently developed and applied by Tianjin Chuangyuan Biotechnology Co., Ltd. was issued by the National Intellectual Property Administration.

This invention provides an application of Weizmannia coagulans IOB502 segmented fermentation agent in alcoholic liver injury, obtained through a two-stage fermentation method.Weizmannia coagulansThe IOB502 strain powder and formulation have high microbial activity and characteristics such as acid and bile salt resistance; at the same time, the Weizmannia coagulans IOB502 strain powder and formulation have high safety.Weizmannia coagulansThe fermented Weizmannia coagulans IOB502 formulation contains rich flavonoid aglycones and isoflavonoid aglycones, which can enhance liver ADH activity, thereby accelerating ethanol metabolism, reducing ethanol concentration in the blood, and providing a good effect in relieving intoxication; in addition, it can also improve liver SOD activity, reduce ethanol damage to the liver, thus achieving liver protection.Weizmannia coagulans)IOB502制剂含有丰富的黄酮苷元及异黄酮苷元组分,可增强肝脏ADH活力从而加快乙醇代谢,降低血液中乙醇浓度,起到较好的解酒作用;此外,还能够提高肝脏SOD活力,减轻乙醇对肝脏的损害,从而达到护肝的效果。

Related News